Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer

Gastric Cancer is one of the leading causes of cancer-related death worldwide, and patients with unresectable locally advanced or metastatic disease have a poor prognosis. This study aims to evaluate the safety and efficacy of radiotherapy combined with CAPOX and SHR-1701, a PD-L1/TGF-β bispecific antibody, in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. By improving local tumor control and enhancing systemic antitumor activity, this study seeks to increase the opportunity for curative-intent resection and improve survival outcomes in patients with advance gastric cancer.

NCT Number	NCT07689851
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions	Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
Enrollment	60 participants
Start Date	2026-07-01
Primary Completion	2028-07-30 (estimated)
Study Completion	2029-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-08